Shares of Vaxcyte, Inc. (PCVX) surged 5.14% in Thursday's pre-market trading session, following a bullish recommendation from a prominent Wall Street analyst. The stock's significant uptick comes as investors react positively to the reiterated confidence in the company's prospects.

Needham analyst Joseph Stringer maintained a Buy rating on Vaxcyte stock, underscoring the firm's optimistic outlook on the biopharmaceutical company. While specific details of the analyst's report were not provided, such endorsements often reflect confidence in a company's long-term potential, financial health, or upcoming catalysts that could drive growth.

The market's strong reaction to this analyst rating suggests that investors are aligning with Stringer's positive view on Vaxcyte. As a clinical-stage vaccine company, Vaxcyte's stock performance can be particularly sensitive to expert opinions and potential advancements in its product pipeline. Investors will likely be watching closely for any further developments or announcements from the company that could sustain this momentum.